News | Contrast Media | April 13, 2016

Global Contrast Media Market to Surpass $6 Billion by 2022

GlobalData report cites increasing burden for diagnostic scans, lack of outside competition

April 13, 2016 — The global market for contrast media is set to rise from just over $4.3 billion in 2015 to over $6 billion by 2022, according to research and consulting firm GlobalData. This represents a compound annual growth rate of 4.9 percent.

The company’s latest report states that this growth — which will occur across the 10 major markets (10MM) of the United States, France, Germany, Italy, Spain, the United Kingdom, Japan, Brazil, China and India — will be driven by a number of factors. These include increases in the number of annual computed tomography (CT), magnetic resonance imaging (MRI) and echocardiogram procedures as well as an increasing disease burden across the 10MM.

Amendeep Sanghera, GlobalData’s analyst covering medical devices, explained, “The contrast media market is old and well-established, with products being used in a wide array of indications. As populations rise across the global, disease rates inevitably grow, along with the need for diagnostic investigations and therefore contrast media.

“Better healthcare systems and education across numerous regions are also driving the contrast media market. For example, there is a particular focus in developed countries to screen patients for certain diseases such as breast and colorectal cancer in order to catch disease early and increase the likelihood of a patient’s survival, and this practice is now spreading to developing countries.”

GlobalData’s report also states that the market has no real competition besides the players already in it, as no other non-invasive imaging modality is able to provide comparative results as quickly, safely and easily to patients. However, generic contrast media manufacturers may acquire market share if they are able develop a reputable brand provided at a lower cost than the four leading market players: GE Healthcare, Bayer, Bracco and Guerbet.

Sanghera added, “Due to excellent safety profiles, image enhancement and wide indication coverage, contrast media have become a mainstay of modern medicine. Nuclear medicine could be a competitor in the future, but for now the contrast media market is in a stable position.”

For more information:

Related Content

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

Feature | Contrast Media Injectors | April 11, 2019 | By Jeff Zagoudis
One of the most controversial issues in radiology in recent years has been the use of...
Non-Contrast MRI Effective in Monitoring MS Patients
News | Neuro Imaging | March 18, 2019
Brain magnetic resonance imaging (MRI) without contrast agent is just as effective as the contrast-enhanced approach...
Ultrasound Societies Urge FDA to Remove "Black Box" on Ultrasound Contrast Agents
News | Ultrasound Imaging | March 07, 2019
National and international ultrasound societies are urging the U.S. Food and Drug Administration to remove the “black...
Sponsored Content | Case Study | Contrast Media | January 30, 2019
The medical imaging market relies heavily on contrast media, injected into patients to increase the contrast of bodil
Sponsored Content | Videos | Contrast Media | January 22, 2019
ITN Contributing Editor Greg Freiherr speaks with Guerb
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
VigiLanz and Cincinnati Children's Commercialize Real-Time Acute Kidney Injury Tracking
News | Contrast Media | November 30, 2018
VigiLanz and Cincinnati Children’s Hospital Medical Center recently announced a collaboration that leverages Cincinnati...
Artificial Intelligence May Help Reduce Gadolinium Dose in MRI

Example of full-dose, 10 percent low-dose and algorithm-enhanced low-dose. Image courtesy of Enhao Gong, Ph.D.

News | Contrast Media | November 27, 2018
Researchers are using artificial intelligence (AI) to reduce the dose of a contrast agent that may be left behind in...